A Two-Part Absolute Bioavailability Study Designed to Evaluate the Pharmacokinetic Profile of Velusetrag Following Single-Dose Administration of Intravenous and Oral Capsule Formulations in Healthy Male and Female Subjects

2024-513988-70-00 Protocol VE-CIP1002/2021 Human pharmacology (Phase I) - Other Ended

Start 7 Oct 2024 · End 21 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol VE-CIP1002/2021

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 20
Countries 1
Sites 1

chronic intestinal pseudo-obstruction (CIPO)

Key facts

Sponsor
Alfasigma S.p.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
7 Oct 2024 → 21 Feb 2025
Decision date (initial)
2024-09-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

chronic intestinal pseudo-obstruction (CIPO)

VersionLevelCodeTermSystem organ class
26.0 LLT 10088266 Chronic intestinal pseudo-obstruction 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Alfasigma S.p.A.

Sponsor organisation
Alfasigma S.p.A.
Address
Via Ragazzi Del '99 5
City
Bologna
Postcode
40133
Country
Italy

Scientific contact point

Organisation
Alfasigma S.p.A.
Contact name
Paolo Battigello

Public contact point

Organisation
Alfasigma S.p.A.
Contact name
Paolo Battigello

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 20 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-10-07 2025-02-21 2024-10-07 2025-01-31

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-29 Netherlands Acceptable
2024-09-10
2024-09-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-12 Netherlands Acceptable
2024-09-10
2024-12-12